Total Payments
$1,380
2023 Payments
$246.26
Companies
10
Transactions
70
Medicare Patients
3,491
Medicare Billing
$844,679
Payment Breakdown by Category
Food & Beverage$1,380 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,380 | 70 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $473.21 | 27 | $0 (2021) |
| Theravance Biopharma, Inc. | $326.01 | 18 | $0 (2018) |
| Inari Medical, Inc. | $219.67 | 2 | $0 (2023) |
| The Medicines Company | $103.63 | 7 | $0 (2017) |
| Gilead Sciences, Inc. | $98.67 | 7 | $0 (2022) |
| Cumberland Pharmaceuticals, Inc. | $39.43 | 3 | $0 (2023) |
| Melinta Therapeutics, Inc. | $39.23 | 2 | $0 (2018) |
| Paratek Pharmaceuticals, Inc. | $28.22 | 2 | $0 (2020) |
| Astellas Pharma US Inc | $25.83 | 1 | $0 (2018) |
| Janssen Pharmaceuticals, Inc | $25.74 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $246.26 | 4 | Inari Medical, Inc. ($219.67) |
| 2022 | $32.10 | 2 | Gilead Sciences, Inc. ($19.26) |
| 2021 | $51.69 | 3 | Gilead Sciences, Inc. ($33.55) |
| 2020 | $57.43 | 3 | Janssen Pharmaceuticals, Inc ($25.74) |
| 2019 | $97.07 | 6 | Merck Sharp & Dohme Corporation ($70.82) |
| 2018 | $268.92 | 15 | Theravance Biopharma, Inc. ($107.90) |
| 2017 | $626.17 | 37 | Merck Sharp & Dohme Corporation ($293.32) |
All Payment Transactions
70 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2023 | Cumberland Pharmaceuticals, Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $13.77 | General |
| Category: INFECTIONS AND INFECTIOUS DISEASES | ||||||
| 09/27/2023 | Cumberland Pharmaceuticals, Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $12.82 | General |
| Category: INFECTIONS AND INFECTIOUS DISEASES | ||||||
| 03/22/2023 | Inari Medical, Inc. | CT THROMBECTOMY SYSTEM KIT (Device), FLOWTRIEVER CATHETER, S | Food and Beverage | In-kind items and services | $187.32 | General |
| Category: VTE | ||||||
| 02/01/2023 | Inari Medical, Inc. | FLOWTRIEVER CATHETER, S (Device), CT THROMBECTOMY SYSTEM KIT | Food and Beverage | In-kind items and services | $32.35 | General |
| Category: VTE | ||||||
| 11/17/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.26 | General |
| 07/27/2022 | Cumberland Pharmaceuticals, Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $12.84 | General |
| Category: INFECTIONS AND INFECTIOUS DISEASES | ||||||
| 12/15/2021 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $18.37 | General |
| 11/02/2021 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $15.18 | General |
| 07/01/2021 | Merck Sharp & Dohme Corporation | DIFICID (Drug), ZERBAXA, RECARBRIO | Food and Beverage | In-kind items and services | $18.14 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/10/2020 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $25.74 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 01/23/2020 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug), RECARBRIO | Food and Beverage | In-kind items and services | $18.37 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/22/2020 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $13.32 | General |
| Category: ANTIBIOTIC | ||||||
| 12/11/2019 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $14.90 | General |
| Category: ANTIBIOTIC | ||||||
| 10/31/2019 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug), SIVEXTRO | Food and Beverage | In-kind items and services | $18.09 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/25/2019 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug), SIVEXTRO | Food and Beverage | In-kind items and services | $15.68 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 06/17/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $11.35 | General |
| 04/18/2019 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug), SIVEXTRO | Food and Beverage | In-kind items and services | $18.78 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/24/2019 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug), SIVEXTRO | Food and Beverage | In-kind items and services | $18.27 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/29/2018 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug), SIVEXTRO | Food and Beverage | In-kind items and services | $19.62 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/24/2018 | Melinta Therapeutics, Inc. | Vabomere (Drug), Orbactiv, MINOCIN | Food and Beverage | In-kind items and services | $19.78 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 10/01/2018 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $11.18 | General |
| 09/20/2018 | Theravance Biopharma, Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $23.73 | General |
| Category: Infectious Disease | ||||||
| 08/30/2018 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug), SIVEXTRO | Food and Beverage | In-kind items and services | $17.10 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/26/2018 | Theravance Biopharma, Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $21.51 | General |
| Category: Infectious Disease | ||||||
| 07/26/2018 | Theravance Biopharma, Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $21.51 | General |
| Category: Infectious Disease | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 490 | 1,836 | $395,055 | $124,264 |
| 2022 | 5 | 794 | 2,455 | $327,275 | $170,790 |
| 2021 | 5 | 1,040 | 3,739 | $489,270 | $264,330 |
| 2020 | 6 | 1,167 | 4,254 | $548,145 | $285,296 |
Total Patients
3,491
Total Services
12,284
Medicare Billing
$844,679
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 195 | 1,374 | $266,556 | $85,169 | 32.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 195 | 296 | $86,136 | $27,541 | 32.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 23 | 35 | $10,762 | $3,201 | 29.7% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 31 | 46 | $10,074 | $3,171 | 31.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 17 | 32 | $9,920 | $2,442 | 24.6% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2023 | 17 | 29 | $6,351 | $1,498 | 23.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 12 | 24 | $5,256 | $1,240 | 23.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 403 | 1,958 | $215,380 | $107,493 | 49.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 305 | 351 | $87,855 | $51,385 | 58.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 51 | 104 | $16,640 | $8,221 | 49.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 18 | 25 | $4,000 | $1,919 | 48.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 17 | 17 | $3,400 | $1,772 | 52.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 515 | 3,063 | $336,930 | $172,810 | 51.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 399 | 469 | $117,495 | $73,694 | 62.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 59 | 113 | $18,080 | $9,351 | 51.7% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 40 | 43 | $8,605 | $4,468 | 51.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 27 | 51 | $8,160 | $4,007 | 49.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 543 | 3,470 | $381,700 | $188,716 | 49.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 424 | 503 | $126,085 | $75,611 | 60.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 72 | 81 | $16,200 | $8,300 | 51.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 43 | 77 | $8,610 | $4,498 | 52.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 34 | 54 | $8,640 | $4,224 | 48.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 36 | 44 | $4,910 | $3,201 | 65.2% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 15 | 25 | $2,000 | $745.80 | 37.3% |
About Emmanuel Frempong-Manso
Emmanuel Frempong-Manso is a Infectious Disease healthcare provider based in Monroeville, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/01/2007. The National Provider Identifier (NPI) number assigned to this provider is 1760679948.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Emmanuel Frempong-Manso has received a total of $1,380 in payments from pharmaceutical and medical device companies, with $246.26 received in 2023. These payments were reported across 70 transactions from 10 companies. The most common payment nature is "Food and Beverage" ($1,380).
As a Medicare-enrolled provider, Frempong-Manso has provided services to 3,491 Medicare beneficiaries, totaling 12,284 services with total Medicare billing of $844,679. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Monroeville, PA
- Active Since 10/01/2007
- Last Updated 10/29/2025
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1760679948
Products in Payments
- VIBATIV (Drug) $365.44
- ZERBAXA (Drug) $208.77
- CT THROMBECTOMY SYSTEM KIT (Device) $187.32
- CUBICIN RF (Drug) $101.16
- MINOCIN IV (Drug) $45.69
- ORBACTIV (Drug) $41.71
- Vabomere (Drug) $39.23
- DIFICID (Drug) $37.90
- NOXAFIL (Drug) $34.95
- FLOWTRIEVER CATHETER, S (Device) $32.35
- NUZYRA (Drug) $28.22
- CRESEMBA (Drug) $25.83
- XARELTO (Drug) $25.74
- ZINPLAVA (Biological) $17.91
- VABOMERE (Drug) $16.23
- ISENTRESS (Drug) $16.16
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.